LIPOCINE INC
LPCNNASDAQTrading Snapshot
- Day Range
- $1.46 – $1.53
- 52-Week Range
- $1.40 – $12.37
- Volume (shares)
- 193,298
- Avg Volume (shares)
- —
- Shares Outstanding
- 8.2M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $190,099
- P/E Ratio
- —
- P/S Ratio
- 7.6x
- EPS (TTM)
- $-1.87
- Dividend Yield
- —
- Dilution (1yr)
- +5.3%
LIPOCINE INC
LPCN
StockOtter · stockotter.spaceAbout LIPOCINE INC
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Here's Why You Should Add LPCN Stock to Your Portfolio Now
Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.
Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada
Health Canada has given the go-ahead to Lipocine Inc. (NASDAQ:LPCN) and its licensing partner, Verity Pharmaceuticals Inc., for TLANDO (testosterone undecanoate) capsules.
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
SALT LAKE CITY, Oct. 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine's licensing part
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?
Lipocine (LPCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
Study informed by encouraging exploratory efficacy findings and a favorable safety profile in the prior Phase 3 trial Approximately 120 participants with severe postpartum depression (PPD) planned; first participant dosi
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
SALT LAKE CITY, Sept. 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that Company management will present